Can’t keep up with allergy shots? Your other options
The schedule is the usual reason people stop allergy shots, not the shots themselves. Here is what else exists, what each one covers, what the evidence says, and when staying on shots is still the better call.
If weekly clinic visits are what stops you, you can still get allergy immunotherapy, the only treatment that retrains the immune system rather than masking symptoms. Four FDA-approved tablets dissolve under the tongue at home and cover grass pollen, short ragweed and house dust mite. Personalized allergy drops can cover several allergens at once, including pets, molds and trees; they are compounded and prescribed off-label, made from FDA-approved allergenic extracts. At-home shots exist, but only under modified protocols for preselected patients, with supervision and epinephrine at hand. Cluster and rush schedules shorten the build-up but raise the reaction risk. Biologics and allergy medicines control symptoms without changing the allergy itself. Stay on shots, or see an allergist in person before switching, if you have venom allergy, severe or uncontrolled asthma, a past reaction to shots, or are pregnant.
Written by Dr. Chet Tharpe, MD · Medically reviewed by Dr. Neeta Ogden, MD, FACAAI · Last reviewed September 2026 · Last verified: September 28, 2026
Why people stop
The schedule, mostly
Allergy shots work. Separate Cochrane reviews found them effective against placebo in 51 trials (Calderón 2007), and they remain the standard of care in US allergy practice. The problem is the calendar: build-up usually means one or two clinic visits a week for three to six months, each followed by a 30-minute observation period, then a visit every two to four weeks for three to five years.
That is hard to keep. In the biggest real-world persistence study, Dutch pharmacy data on 6,486 patients, only 23% of people on shots were still on them at three years (Kiel 2013). If you have stopped, or never started because of the visits, you are in the majority, and stopping early is how the benefit is lost. The question worth asking is which route you can realistically finish.
Two things before you switch. First, tell the clinician who prescribed your shots; if you stop partway, restarting any route usually means a new build-up. Second, keep taking the medicines that control your symptoms today while you decide.
At a glance
The alternatives side by side
Only the first four rows are immunotherapy — treatment that changes how the immune system responds. The last two control symptoms.
| Option | What it is | Allergens covered | Where and how often | Main caveat |
|---|---|---|---|---|
| FDA-approved allergy tablets | A dissolving tablet under the tongue (sublingual immunotherapy, SLIT) | One allergen group per tablet: grass pollen, short ragweed or house dust mite | Daily at home after a first dose observed in clinic | Nothing for pets, molds, trees or other weeds; epinephrine auto-injector prescribed |
| Personalized allergy drops | Liquid drops under the tongue, mixed for your test results (SLIT) | Several at once, including pets, molds, trees and weeds | Daily at home; clinician visits can be remote | Compounded and prescribed off-label; the 2017 US practice parameter did not endorse drops; usually self-pay |
| At-home allergy shots | The same injections, given at home under a modified protocol | Same as clinic shots | At home, on the shot schedule | Only for preselected lower-risk patients, with supervision, a trained adult and epinephrine at home |
| Accelerated shot schedules | Cluster or rush build-up in clinic | Same as clinic shots | Fewer, longer build-up visits; maintenance still in clinic | More systemic reactions during build-up |
| Biologics | Injected antibodies such as omalizumab or dupilumab | Not allergen-specific | Every 2–4 weeks, often indefinitely | Treat asthma, nasal polyps, eczema, hives or food-allergy reactions; not a treatment for hay fever on its own; do not retrain the immune system |
| Medicines and avoidance | Antihistamines, nasal steroid sprays and other symptom medicines; reducing exposure | Not allergen-specific | Daily or as needed | Help you feel better today; stop working when you stop taking them |
Sources: FDA product pages for Grastek, Oralair, Ragwitek and Odactra; AAAAI/ACAAI SLIT practice parameter 2017; Schaffer 2015; Bernstein and Epstein 2020. Checked September 28, 2026.
Option 1
The four FDA-approved allergy tablets
These are the only sublingual immunotherapy products the FDA has approved. Each treats allergic rhinitis, with or without allergic conjunctivitis, confirmed by a skin or blood test to that allergen.
| Tablet | Allergen | Approved ages | FDA page |
|---|---|---|---|
| Grastek | Timothy grass and cross-reactive grass pollens | 5 through 65 | fda.gov/grastek |
| Oralair | Five grasses: sweet vernal, orchard, perennial rye, Timothy, Kentucky blue | 5 through 65 | fda.gov/oralair |
| Ragwitek | Short ragweed pollen | 5 through 65 | fda.gov/ragwitek |
| Odactra | House dust mite (D. farinae, D. pteronyssinus) | 5 through 65 | fda.gov/odactra |
From the FDA product pages and prescribing information, read September 28, 2026. Every label carries a boxed warning for severe allergic reactions, requires the first dose in a doctor’s office with 30 minutes of observation, and asks the prescriber to provide an epinephrine auto-injector. The grass and ragweed tablets are started at least 12 weeks before the pollen season (Grastek label).
Who the tablets fit
Tablets are the most thoroughly regulated alternative: standardized doses, large placebo-controlled trials, and FDA approval. They fit best if one allergen dominates your symptoms — grass season, ragweed season or year-round dust mite. They are usually filled at a pharmacy and may be covered by prescription insurance.
The limit is coverage. Most people who were on shots were being treated for several allergens at once, and there are no tablets for cats, dogs, molds, trees or most weeds. You can take more than one tablet only as your prescriber directs; each is a separate product with its own schedule.
Option 2
Personalized allergy drops
Personalized drops use the same kind of allergen extracts as shots, mixed for your test results and taken under the tongue every day at home. Because the mixture is made for you, one bottle can cover several allergens — the practical reason people switching from multi-allergen shots look at drops.
Drops are compounded and prescribed off-label, made from FDA-approved allergenic extracts; off-label does not mean unsafe or experimental, and it is a long-standing practice. The evidence for sublingual immunotherapy overall is substantial: a Cochrane review of 60 trials found it reduced symptoms and medication use against placebo (Radulovic 2010). But most of that evidence comes from single-allergen products, and the 2017 AAAAI/ACAAI practice parameter declined to endorse customized aqueous drops on the evidence then available (PMID 28284533). Both facts belong in the decision.
Real-world data on multi-allergen drops is growing. A 2026 retrospective study of 2,897 adults treated through Curex reported clinically meaningful symptom improvement in 28% of patients at 12 months and 45% at 24 months (Tharpe 2026). It had no comparison group, included only people with at least a year of follow-up, and was written by Curex clinicians, so read it as encouraging rather than conclusive.
Drops are usually self-pay; insurance often covers the testing and consultations but rarely the drops themselves. Curex’s current plans are on getcurex.com/pricing; compare other providers at allergy drops providers compared. For the full trade-off, see allergy drops vs allergy shots.
Option 3
Allergy shots at home
Allergy shots are safe and effective, but they cause more systemic reactions than sublingual treatment, which is why US practice parameters advise giving them in a medical setting equipped to treat anaphylaxis, with a 30-minute wait afterwards (Cox 2011). Giving them at home is possible only with a protocol built for it.
Those protocols share four features: patient preselection that excludes higher-risk people (for example, uncontrolled asthma or a past systemic reaction); a slower build-up; supervision by the prescribing practice; and epinephrine at home with an adult trained to use it. The largest published safety analysis, of 23,614 preselected patients who self-administered about two million injections over one year, reported a systemic reaction rate of 0.16% per patient and no deaths (Schaffer 2015). The study was written by the company that runs the protocol, and its results apply to preselected patients on that protocol, not to anyone giving shots at home.
Ask your own allergist whether you would qualify. If you are told you would not, that answer is the protocol working.
Option 4
Faster shot schedules: cluster and rush
If the build-up is the problem rather than the maintenance, ask about an accelerated schedule. Cluster immunotherapy gives several injections at each visit, so maintenance is reached in weeks instead of months; rush immunotherapy reaches it over one to a few days in a monitored setting. After that, maintenance visits continue every few weeks as usual.
The trade-off is safety. Accelerated build-up is a recognized risk factor for systemic reactions in US surveillance data (Bernstein and Epstein 2020), so clinics often premedicate. In one trial, pretreatment with omalizumab cut the risk of anaphylaxis during rush immunotherapy for ragweed about five-fold (Casale 2006) — a research approach, not a routine one.
What biologics do and do not do
Biologics are not a replacement for immunotherapy
Biologics are injected antibodies that block one step of the allergic response. Omalizumab (Xolair), dupilumab (Dupixent) and others are FDA-approved for conditions such as allergic asthma, chronic nasal polyps, eczema and chronic hives, and they can be life-changing for those conditions. None is approved to treat hay fever on its own.
In February 2024 the FDA approved omalizumab to reduce allergic reactions after accidental exposure to one or more foods (FDA announcement; Wood 2024). It protects only while you keep taking it. Biologics do not retrain the immune system to a specific allergen; the protection fades when the injections stop, and they are expensive. In some clinics a biologic is used alongside immunotherapy to make the build-up safer — the biologic protects, the immunotherapy changes the disease.
Always an option
Medicines and avoidance
Antihistamines, steroid nasal sprays, eye drops and, for asthma, controller inhalers help you feel better today, and they are the right place to be while you decide on anything else. Reducing exposure — dust-mite covers, a HEPA filter, keeping pets out of the bedroom, showering after time outdoors in season — adds to them. Symptom medications help you feel better today; only immunotherapy changes the disease.
Safety first
Who should stay on shots, or see an allergist in person before switching
- Insect-sting (venom) allergy. Shots are the immunotherapy for venom allergy; tablets and drops are not used for it. Do not stop venom shots without your allergist.
- Severe, unstable or poorly controlled asthma. The tablets are contraindicated in it (Grastek label), and uncontrolled asthma is the factor most often linked to severe reactions to shots (Bernstein and Epstein 2020). Get the asthma controlled first.
- A past systemic reaction or anaphylaxis to immunotherapy. An allergist should review what happened before you start any other route.
- Pregnancy. Immunotherapy is not usually started during pregnancy; if you are already on a maintenance dose, your clinician may continue it without increasing it (Cox 2011). Tell your prescriber as soon as you know.
- Beta-blockers or heart disease. These can make a severe reaction harder to treat; the tablet labels flag them, and so should any prescriber.
- Young children, and anyone with a suspected food or drug allergy. Start with an in-person evaluation.
- Shots that are working and a schedule you can keep. Then the best alternative may be no alternative. Finishing the course is what makes the benefit last.
Regulation
What is FDA-approved and what is not
Allergy shots use FDA-licensed allergenic extracts by their labelled route. The four tablets above are FDA-approved products. Personalized allergy drops are compounded and prescribed off-label, made from FDA-approved allergenic extracts, the same as in allergy shots; off-label does not mean unsafe or experimental. Biologics are FDA-approved for the specific conditions on their labels.
Regulatory record
Personalized allergy drops, for environmental or food allergy, are made from FDA-approved allergenic extracts and prescribed off-label — a long-standing, legitimate practice that applies to every drops provider, not only Curex. Only a few single-allergen sublingual tablets are FDA-approved.
Has the FDA written to Curex about allergy drops? Once, in 2021: an untitled letter about how the drops were marketed. Curex changed its website, responded in April 2021, and has had no FDA correspondence about allergy drops since.
Does the 2025 FDA warning letter concern allergy drops? No. The September 2025 warning letter concerned marketing language for compounded GLP-1 weight-loss products; Curex made the requested changes.
Every letter and response: Curex and the FDA. The short version: Is Curex legit?
Next step
Where to go from here
If a single allergen drives your symptoms, ask your allergist or primary care doctor about a tablet. If you were on shots for several allergens and the visits are the problem, compare allergy drops and allergy shots and the providers who offer drops; Curex plans are on getcurex.com/pricing. If you are unsure whether you need to be seen in person, read what an allergist does and which parts an online service can do.
❓Frequently Asked Questions
The alternatives that still change the allergy are FDA-approved sublingual tablets (grass, short ragweed, house dust mite), personalized allergy drops for several allergens (compounded and prescribed off-label from FDA-approved extracts), at-home shots under a modified protocol for preselected patients, and faster cluster or rush shot schedules. Biologics, antihistamines, nasal sprays and avoidance control symptoms but do not retrain the immune system.
For the allergen they target, the FDA-approved tablets reduced symptoms and medication use in large placebo-controlled trials, and they are taken at home after a first observed dose. Each covers one allergen group only — grass, short ragweed or dust mite — so they suit people whose symptoms are driven by one of those. Shots can cover many allergens at once and have the longest track record.
Often, yes, but talk to the clinician who prescribed your shots first. Switching usually means a new build-up on the new route, your recent test results may be reused, and people with venom allergy, severe or uncontrolled asthma, a past reaction to immunotherapy, or a pregnancy should be evaluated in person before any switch.
Only under protocols designed for it: preselection that excludes higher-risk patients, a slower build-up, supervision by the prescribing practice, and epinephrine at home with a trained adult. US practice parameters otherwise advise giving shots in a medical setting with a 30-minute observation period.
Not for hay fever. Omalizumab (Xolair) is FDA-approved for allergic asthma, nasal polyps, chronic hives and, since 2024, to reduce reactions after accidental exposure to foods. It blocks IgE while you keep taking it but does not retrain the immune system to a specific allergen, and the protection fades when injections stop.
People treated for insect-venom allergy, anyone whose shots are working on a schedule they can keep, and anyone with severe or poorly controlled asthma or a past systemic reaction should talk to their allergist before changing course. If you are pregnant, immunotherapy is not usually started, but an existing maintenance dose may be continued.
FDA-approved tablets are filled at a pharmacy and may be covered by prescription insurance. Personalized drops are usually self-pay, although insurance often covers testing and consultations; Curex lists its current plans at getcurex.com/pricing. Biologics are expensive and require insurance approval. At-home and accelerated shots are billed like clinic shots.
If you experience sudden difficulty breathing, throat swelling, or other signs of anaphylaxis, call 911. A prescribed epinephrine auto-injector is the first-line treatment — not antihistamines.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Curex provides personalized sublingual immunotherapy and publishes this page. Product facts are from FDA product pages and prescribing information read on September 28, 2026; they change and should be checked with your prescriber.
Sources and record
Where the facts come from
Sources
- FDA: Grastek (Timothy grass pollen allergen extract) product page and prescribing information
- FDA: Oralair (five-grass pollen allergen extract) product page
- FDA: Ragwitek (short ragweed pollen allergen extract) product page
- FDA: Odactra (house dust mite allergen extract) product page
- Grastek prescribing information (boxed warning, contraindications, adverse reactions)
- Calderón MA et al. Cochrane review of allergy shots, 51 trials (PMID 17253469)
- Radulovic S et al. Cochrane review of sublingual immunotherapy, 60 trials (PMID 21154351)
- AAAAI/ACAAI sublingual immunotherapy practice parameter update, 2017 (PMID 28284533)
- Kiel MA et al. J Allergy Clin Immunol 2013 — real-life persistence with SCIT and SLIT, 6,486 patients (PMID 23651609)
- Cox L et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011 (PMID 21122901)
- Schaffer FM et al. Int Forum Allergy Rhinol 2015 — safety of self-administered allergen immunotherapy, 23,614 patients (PMID 25476041)
- Bernstein DI, Epstein TEG. Allergy Asthma Proc 2020 — safety of allergen immunotherapy in North America, 2008–2017 (PMID 32122446)
- Casale TB et al. J Allergy Clin Immunol 2006 — omalizumab pretreatment before rush immunotherapy (PMID 16387596)
- Wood RA et al. N Engl J Med 2024 — omalizumab for multiple food allergies (PMID 38407394)
- FDA, February 2024: omalizumab approved to reduce allergic reactions after accidental food exposure
- Tharpe C et al. Front Allergy 2026 — 2,897-patient telemedicine SLIT cohort (PMID 42358593)
- getcurex.com/pricing
Last verified September 28, 2026. Last updated September 28, 2026 · next scheduled review December 2026.
Change log
- — Published: alternatives to allergy shots — FDA-approved tablets (checked against FDA product pages and labels), personalized drops, at-home shots, accelerated schedules, biologics and medicines — with who should stay on shots. Author Dr. Chet Tharpe, MD; medical reviewer Dr. Neeta Ogden, MD.
Keep reading
- Allergy drops safetyWhat reactions are normal, when to hold a dose, and when to use epinephrine and call 911.Read
- Is Curex legit?The company, the evidence, and the concerns worth knowing — including every FDA letter Curex has received, and what was done about each.Read
- Curex and the FDATwo separate matters: the 2021 allergy-drops questions and the 2025–2026 GLP-1 marketing letters, with what Curex changed.Read
- How Curex worksThe treatment process end to end, from at-home testing to daily drops.Read
- Curex reviewsWhat patients actually report — both clusters, including the complaints.Read
- Is Curex worth the money?Plan pricing against allergy-shot costs, and who it is not worth it for.Read